TH

Thermogenesis Holdings IncNASDAQ THMO Stock Report

Last reporting period 31 Mar, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

0.003

Micro

Exchange

XNAS - Nasdaq

THMO Stock Analysis

TH

Uncovered

Thermogenesis Holdings Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-30/100

Low score

Market cap $B

0.003

Dividend yield

Shares outstanding

1.037 B

ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. The company is headquartered in Rancho Cordova, California and currently employs 39 full-time employees. The firm provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for large scale cell manufacturing services. The company manufactures and markets three categories of products, Clinical Bio-Banking Applications, Point-of-Care Applications, and Large Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications includes AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Point-of-Care Applications includes PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory useand CAR-TXpress Platform for clinical manufacturing.

View Section: Eyestock Rating